A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years

Trial Profile

A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Diphencyprone (Primary)
  • Indications Warts
  • Focus Therapeutic Use
  • Sponsors RXi Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2017 According to a RXi Pharmaceuticals media release, the company expects early read-outs before the end of this year.
    • 06 Sep 2017 Status changed from recruiting to active, no longer recruiting, according to an RXi Pharmaceuticals Corporation media release.
    • 11 May 2017 According to a RXi Pharmaceuticals media release, the company expects early read-outs in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top